The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study.

The Efficacy and Safety of Alectinib in Clinical Practice ; Comparision to Crizotinib, in A Multicenter Retrospective Study. - The efficacy of alectinib in a multicenter retrospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036255

Enrollment

Registered

2019-03-19

Start date

2016-03-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK rearranged non-small-cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who had ALK rearrangement positive results for sensitive immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), or reverse-transcriptase polymerase-chain-reaction (RT-PCR), and all patients with positive results for FISH had more than 15% split signals.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Time to treatment failure	—

Secondary

Measure	Time frame
Progression-free survival Overall survival	—

Countries

Japan

Contacts

Public ContactKentaro Ito

Matsusaka Municipal Hospital Respiratory centor

kentarou_i_0214@yahoo.co.jp0598-23-1515

Outcome results